Month-by-month tracking of the prices paid in India for the
chemicals used to make hepatitis C direct-acting antivirals shows that it is
now possible to make and sell a combination of drugs to cure hepatitis C for
less than $200, Dr Andrew Hill of Liverpool University told the Second European
HIV Hepatitis Co-infection Conference in London last week.
If those drugs were bought at list price in the United States they would cost approximately $147,000 for a 12-week course of treatment –
$84,000 for sofosbuvir (Sovaldi), manufactured by Gilead Sciences, and $63,000 for daclatasvir (Daklinza), manufactured by Bristol-Myers Squibb.
Tracking of shipments of active pharmaceutical ingredients
(API) by indiainfodrive.com, a
reporting mechanism for importers and exporters, shows that the value of
shipments of the APIs that are used to make sofosbuvir (Sovaldi), the world’s most frequently-prescribed hepatitis C direct-acting antiviral, has fallen
from around $8000 per kilogram in January 2015 to around $2000 per kg by
September 2015.
Active pharmaceutical ingredients are manufactured in India
and China and shipped to other parts of the world for final manufacture of a
drug. Indiainfodrive.com tracks shipments in and out of India for a wide range
of commodities by analysing customs data, which must declare the weight and
value of items passing through customs.
By crunching these data, Andrew Hill and colleagues were
able to track changes in the value of shipments of the APIs used in the
manufacture of sofosbuvir and of daclatasvir. Using these prices, they went on to calculate how much
it would cost to manufacture a finished product, using methods of calculation
already validated for the estimation of antiretroviral costs. In the case of
sofosbuvir, they found that even assuming a 50% profit margin for the
manufacturer to cover capital investment and return to shareholders, it would
now be possible to sell a 12-week course of the drug for $178.
“The supplies in 2015 are sufficient to treat 150,000 people
with sofosbuvir, for 12 weeks. Even at these quite low volumes the prices
have fallen by 70% in one year, and there is no sign of a levelling off in
prices,” Dr Hill told aidsmap.com by
email.
Indian manufacturers are already making generic versions of
sofosbuvir under voluntary licensing agreements with Gilead Sciences, selling
for around $483 for a 12-week course of treatment in India. In comparison a
generic version of sofosbuvir – again, manufactured under voluntary license –
is sold for $900 in Egypt. The branded product Sovaldi, manufactured by Gilead, costs $27,921 in Spain and $53,010
in the United Kingdom (although prices paid might be considerably lower due to
negotiations regarding volume).
Daclatasvir would be even cheaper. The cost of its active
ingredients have fallen from around $10,000 per kg in January 2015 to $2000 per
kg in September, implying a generic cost of $22 for a 12-week course of
treatment rather than the $63,000 list price currently charged in the United
States. This low price may be achievable imminently, Hill believes, as a result
of the licensing of daclatasvir to the Medicines Patent Pool for lower-income
countries.
These costings suggest that it would be possible to market a
pan-genotypic combination of sofosbuvir and daclatasvir for no more than $200.
But many of the middle-income countries with a high burden of hepatitis C, such
as China, Brazil, Ukraine and Latin America, will continue to be excluded by
the terms of voluntary licensing agreements from obtaining Indian generics –
unless they pursue compulsory licensing. Dr Hill reminded the conference that
the South African government’s threat to use compulsory licensing had been
critical in opening the way to lower antiretroviral drug prices in the early
2000s.
In the case of hepatitis C treatment, people could take
matters into their own hands without waiting for governments. In Australia the FixhepC
buyers club is working to assist individuals in buying generic drugs to treat
hepatitis C, carrying out quality testing to ensure that they contain active
pharmaceuticals, and importing the drugs for personal use. (The FixhepC
website contains details of import regulations regarding medication for
personal use for Australia, New Zealand, the United Kingdom and United States,
as well as details of how people can purchase medication from generic
manufacturers).
Hill also challenged the claim that current US pricing of Sovaldi and Harvoni makes the drugs cost-effective. He pointed out that at
current prices, the use of the drugs is only cost-effective when set against a
lifetime of medical costs, and calculations of cost-effectiveness ignore the
propensity of drug prices to fall over time. Similarly, claims that treatment
at current prices is cost saving are misleading, Hill argued, pointing to
recent projections published in the Annals of Internal
Medicine. Jagpreet Chhatwal and colleagues found that treating all eligible
patients with hepatitis C in the United States over the next five years would
cost $65 billion, but would save only $16 billion in medical costs over the
same period.
The current levels of pricing are only sustainable, Hill believes,
for as long as Gilead lacks price competition in developed world markets and
faces no serious threat of compulsory licensing in middle-income markets.
“It only takes one company to be brave and say `we aren’t
going to charge £30,000, we’re going to charge £10,000`, and they will make a
lot of money,” Dr Hill concluded, to prolonged applause.